TP53 and cancer: Of note, disruption of the RPL11-MDM2-p53 pathway remarkably accelerated oncogenic Myc-induced tumorigenesis (Macias et al. 2010), further implying that RPL11-MDM2 interaction could be an anti-cancer drug target.